All News
Filter News
Found 73,707 articles
-
We have known since early on that diabetes is a complicating risk factor for developing severe illness from the SARS-CoV-2 virus that causes COVID-19. The hypothesis is now being floated by members of the medical community that COVID-19 may cause the disease to return – or potentially a unique ve...
-
Clinical Chemistry Analyzer Has Utility in Multiple Laboratory Settings and During COVID-19 Crisis with its Small Size and Vast Menu
11/18/2020
The Medica EasyRA® benchtop clinical chemistry analyzer, distributed and serviced by Greensboro-based company, Carolina Liquid Chemistries Corp. (CLC), allows healthcare providers to test routine blood chemistries to include metabolic panels, liver enzymes, kidney function tests, glucose and cardiovascular tests.
-
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
11/18/2020
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the completion of a Type A meeting with the U.S. Food and Drug Administration (FDA) confirming a pathway for resubmission for approval of the Company’s drug candidate Libervant
-
Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature
11/18/2020
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for DEFINITY® Room Temperature
-
Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
11/18/2020
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2020, and provided a corporate update
-
BERJAYA GROUP SIGNS STRATEGIC TELEMEDICINE COOPERATION AGREEMENT WITH LYTUS TECHNOLOGIES
11/18/2020
British Virgin Island headquartered Lytus Technologies Holdings Private Limited (Lytus), a technology-platforms company that offers streaming and telemedicine services with business operations in the United States and India, has signed a strategic business cooperation agreement with Singapore based True Healthcare Pte Limited (True Health).
-
Quanterix Appoints William Geist as Chief Operating Officer
11/18/2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has named William Geist to the position of chief operating officer (COO), effective November 16, 2020.
-
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior Notes
11/18/2020
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced and upsized its previously announced offering of $1.0 billion aggregate principal amount of 5.000% senior notes due 2029 (the "2029 Notes") and $1.0 billion aggregate principal amount of 5.250% senior notes due 2031 (the "2031 Notes" and, together with the 2029 Notes, the "Notes")
-
Syneos Health Announces Upsizing and Pricing of Offering of $600.0 Million of Senior Notes Due 2029
11/18/2020
Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the upsizing and pricing of an offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”)
-
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
11/18/2020
Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on November 17, 2020 issued a composition of matter patent, U.S. Patent No. 10,837,028
-
Ixlayer Introduces Technology to Accelerate the Safe Distribution of Forthcoming COVID-19 Vaccine
11/18/2020
Today, ixlayer, a leader in technology-based solutions for healthcare management, announced a new platform to optimize and accelerate the highly-complex process of distributing COVID-19 vaccines while managing the response to the virus
-
Inpixon Mapping Selected by Leading Pharmaceutical Corporation to Facilitate Tracking of COVID-19 Vaccine-Related Assets
11/18/2020
Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that Inpixon Mapping has been selected by one of the world's premier pharmaceutical companies to provide the visualization required for tracking its critical COVID-19 vaccine-related assets.
-
Bayer Fund Awards $3.9 Million in Grants throughout the United States
11/18/2020
Bayer Fund, a philanthropic arm of life sciences company Bayer, today awarded $3.9 million in grants to 80 charities and non-profit organizations throughout the United States, $300,000 of which is dedicated to supporting initiatives related to COVID-19. Each grant will go toward a program that contributes to one or more of Bayer Fund’s
-
Vivera Pharmaceuticals Partners with EcoGroup USA in the Distribution of its BioZone Sanitizing Stations
11/18/2020
Vivera Pharmaceuticals is excited to announce a distribution partnership with EcoGroup USA for Vivera's BioZone, an advanced access control device intended for sanitization in high occupancy settings. BioZone is designed to combine facial recognition, integrated biometrics, and a hospital grade FDA and EPA approved organi
-
Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat
11/18/2020
Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to humans.
-
Melmark Receives Transformational Endowment Gift
11/18/2020
Melmark is pleased to announce the receipt of a $21.5 million endowment gift from the Anne and Brutus Kenan fund to further secure the not-for-profit organization's mission well into the future. Melmark provides clinically-
-
Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Test for Self-Testing at Home
11/18/2020
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home and that provides rapid results. The Lucira COVID-19 All-In-One Test Kit is a molecular (real-time loop mediated amplification reaction) single use test that is intended to
-
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
11/18/2020
PLX-R18 d emonstrated significant c linical improvements in Hb, ANC, and PLT among the high-dose cohort PLX-R1 8 was found to be safe and well-tolerated T opline results from the full Phase I clinical trial expected in Q1 2021 (n=21)
-
Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
11/18/2020
RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT – – RAPID investigates efficacy of second dose of etripamil for patients with persistent PSVT – – RAPID results expected late 2021/early 2022 –
-
GoMeyra LIMS Announces National Lab and Medical Practice Clients as COVID-19 Propels Surge in Demand for New Lab Tech Software System
11/18/2020
GoMeyra, an innovative new software company dedicated to providing revolutionary tech solutions for medical laboratories, announces its roster of national labs and medical practice clients now utilizing the proprietary system, GoMeyra LIMS.